8-K/A: Synlogic Delists from Nasdaq, Moves to OTCQB

Synlogic, Inc. has withdrawn its Nasdaq listing appeal and will delist, planning to trade on the OTCQB Venture Market after being deemed a public shell.

Summary

• Synlogic, Inc. (SYBX) filed an Amendment No. 1 to its Current Report on Form 8-K, amending and restating a previous filing from January 20, 2026.
• The amendment includes Item 8.01 to state that the Company believes it is a 'public shell' under Nasdaq rules.
• It also amends Item 3.01 to disclose the tier of the OTC Markets Group, Inc. upon which the Company expects its shares of common stock to be quoted.
• Nasdaq's Listing Qualifications Department previously notified Synlogic on November 21, 2025, of its belief that the company is a public shell, warranting delisting.
• Synlogic initially requested a hearing on November 28, 2025, which temporarily stayed the suspension and delisting.
• The company withdrew its request for a hearing on January 16, 2026, determining it was no longer in its best interest to pursue continued Nasdaq listing.
• As a result, Nasdaq will suspend trading of Synlogic's common stock at the open of business on January 21, 2026.
• Synlogic expects and plans for its shares to be quoted on the OTCQB Venture Market of OTC Markets Group, Inc., and has submitted an application.
• The company will continue to remain a reporting company under the Securities Exchange Act of 1934, and the transition to OTC is not expected to affect business operations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development, reflecting a significant downgrade in the company's market standing and liquidity due to delisting and the 'public shell' designation.

Positives

• The Company will continue to remain a reporting company under the Securities Exchange Act of 1934.
• The transition to OTC is not expected to affect the Company’s business operations.

Negatives

• Delisting from The Nasdaq Capital Market.
• Nasdaq Staff's belief that the company is a 'public shell' under Nasdaq rules.
• Suspension of trading on Nasdaq effective at the open of business on January 21, 2026.

Risks

• Forward-looking statements are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond the Company's control.
• Actual results and the timing of events may differ materially from the results included in forward-looking statements.
• Investors are cautioned not to place undue reliance on forward-looking statements.
• A list and description of risks, uncertainties, and other factors that could cause or contribute to differences in the Company’s results can be found in its filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent filings.

Future Outlook

Synlogic expects and plans for its shares of common stock to be quoted by the OTCQB Venture Market upon delisting from Nasdaq. The company will continue to remain a reporting company under the Securities Exchange Act of 1934, and the transition to OTC is not expected to affect business operations.

Management Comments

• "The Company has determined that it is no longer in its best interest to pursue continued listing of its common stock on The Nasdaq Capital Market."
• "The Company believes that it is a public shell under the Nasdaq rules."
• "The transition to OTC is not expected to affect the Company’s business operations."

Industry Context

StockSavvy.ai notes that delisting from a major exchange like Nasdaq to the OTCQB Venture Market typically signals a significant decline in a company's operational or financial standing, often due to failure to meet listing requirements or strategic decisions to reduce compliance costs. This move places Synlogic in a less liquid and less transparent trading environment compared to its peers on major exchanges.

Comparison to Industry Standards

• Delisting from Nasdaq is a significant negative event, contrasting sharply with companies that maintain or upgrade their listings on major exchanges like the NYSE or Nasdaq Global Select Market.
• For example, a company like Moderna (MRNA) or Biogen (BIIB) maintains robust listing standards, reflecting strong financial health and corporate governance.
• Synlogic's situation indicates a failure to meet these benchmarks, particularly the 'public shell' designation, which is a severe deviation from industry best practices for publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience reduced liquidity, potentially lower valuation, and decreased transparency due to trading on the OTCQB Venture Market instead of Nasdaq. The 'public shell' designation could also deter new investors.
• Employees: The filing states the transition to OTC is not expected to affect business operations, implying minimal immediate impact on employees.
• Customers/Suppliers: The filing states the transition to OTC is not expected to affect business operations, implying minimal immediate impact on customers and suppliers.

Next Steps

• Nasdaq is expected to file a Form 25 Notification of Delisting with the Securities Exchange Commission when all internal procedural periods have run.
• The Company expects and plans for its shares of common stock to be quoted by the OTCQB Venture Market.
• The Company will make additional disclosures relating to post-suspension trading as that information becomes available.

Key Dates

Recommendation

The delisting from Nasdaq, coupled with the 'public shell' designation and the move to the less liquid OTCQB market, represents a severe negative event for Synlogic. This significantly diminishes the company's visibility, investor confidence, and access to capital, making it a high-risk investment with substantial downside potential. Seasoned investors would likely divest to avoid further value erosion and seek more stable opportunities.

Keywords

Synlogic, SYBX, Nasdaq delisting, OTCQB, public shell, SEC filing, stock suspension, corporate governance, financial reporting